[go: up one dir, main page]

AR036384A1 - Una proteina de fusion que tiene actividad de eritropoyetina in vivo aumentada - Google Patents

Una proteina de fusion que tiene actividad de eritropoyetina in vivo aumentada

Info

Publication number
AR036384A1
AR036384A1 ARP020103279A ARP020103279A AR036384A1 AR 036384 A1 AR036384 A1 AR 036384A1 AR P020103279 A ARP020103279 A AR P020103279A AR P020103279 A ARP020103279 A AR P020103279A AR 036384 A1 AR036384 A1 AR 036384A1
Authority
AR
Argentina
Prior art keywords
increased
fusion protein
activity
erythropoyetin
vivid
Prior art date
Application number
ARP020103279A
Other languages
English (en)
Inventor
Dong-Eok Lee
Myung-Suk Oh
Bo-Sup Chung
Ji-Sook Park
Ki-Wan Kim
Original Assignee
Cheil Jedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheil Jedang Corp filed Critical Cheil Jedang Corp
Publication of AR036384A1 publication Critical patent/AR036384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una proteína de fusión que tiene actividad de eritropoyetina in vivo aumentada en donde un fragmento de péptido del extremo carboxilo terminal de tromboyetina es fusionado con el extremo carboxilo terminal de la eritropoyetina humana. Esta proteína de fusión tiene una vida media in vivo muy aumentada debido al contenido aumentado de carbohidratos sin pérdidas de la actividad inherente de la eritropoyetina, y no provoca ninguna antigenicidad cuando se aplica al cuerpo humano.
ARP020103279A 2001-11-29 2002-08-30 Una proteina de fusion que tiene actividad de eritropoyetina in vivo aumentada AR036384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0074975A KR100467750B1 (ko) 2001-11-29 2001-11-29 생체내 에리스로포이에틴 활성이 증진된 융합단백질

Publications (1)

Publication Number Publication Date
AR036384A1 true AR036384A1 (es) 2004-09-01

Family

ID=36821313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103279A AR036384A1 (es) 2001-11-29 2002-08-30 Una proteina de fusion que tiene actividad de eritropoyetina in vivo aumentada

Country Status (23)

Country Link
US (1) US7098318B2 (es)
EP (1) EP1319712B1 (es)
JP (1) JP3860097B2 (es)
KR (1) KR100467750B1 (es)
CN (1) CN100390201C (es)
AR (1) AR036384A1 (es)
AT (1) ATE460483T1 (es)
AU (1) AU2002300359B2 (es)
BR (1) BRPI0203394B1 (es)
CA (1) CA2394572C (es)
DE (2) DE10235248B4 (es)
ES (1) ES2339426T3 (es)
FR (1) FR2832716B1 (es)
GB (1) GB2382580B (es)
IT (1) ITMI20021803A1 (es)
MX (1) MXPA02008131A (es)
MY (1) MY122935A (es)
NZ (1) NZ520442A (es)
RU (1) RU2225220C1 (es)
SG (1) SG117416A1 (es)
TW (1) TWI237056B (es)
WO (1) WO2003046013A1 (es)
ZA (1) ZA200206172B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
JP2007517769A (ja) * 2003-09-29 2007-07-05 ウォーレン ファーマシューティカルズ，インコーポレーテッド 敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
CN101863982A (zh) * 2009-04-17 2010-10-20 哈药集团生物工程有限公司 一种用于升高血小板的融合蛋白及其制备方法
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN103864913A (zh) 2012-12-18 2014-06-18 联亚生技开发股份有限公司 重组蛋白
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PH12017501089B1 (en) 2014-12-10 2022-06-22 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
KR102172937B1 (ko) 2015-06-19 2020-11-03 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법
SG10202100189WA (en) 2016-07-11 2021-02-25 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029799T2 (de) * 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
KR100263845B1 (ko) * 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
BR9406490A (pt) * 1993-04-29 1996-03-05 Abbott Lab Análogo de eritropoietina humana,DNA de filamento duplo,vetor de expressão célula de mamiferos em cultura composição farmaceutica segundo e terceiro análogo de eritropoietina humana e processos para fabricar um segundo análogo de eritropoietina e para usar um segundo análogo
IL110669A (en) * 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
JPH11500308A (ja) * 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー 新規ｃ−ＭＰＬリガンド
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999057147A1 (fr) * 1998-04-30 1999-11-11 Kirin Brewery Company, Limited Mutants de la thrombopoietine humaine
US6548653B1 (en) * 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
DE60040225D1 (en) * 1999-07-13 2008-10-23 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態

Also Published As

Publication number Publication date
CN1421461A (zh) 2003-06-04
NZ520442A (en) 2003-10-31
CN100390201C (zh) 2008-05-28
MY122935A (en) 2006-05-31
CA2394572C (en) 2007-08-14
EP1319712A2 (en) 2003-06-18
FR2832716B1 (fr) 2004-12-03
ATE460483T1 (de) 2010-03-15
CA2394572A1 (en) 2003-05-29
AU2002300359B2 (en) 2004-12-23
ZA200206172B (en) 2003-04-03
KR20030044272A (ko) 2003-06-09
SG117416A1 (en) 2005-12-29
DE10235248A1 (de) 2003-06-12
DE10235248B4 (de) 2004-12-23
US7098318B2 (en) 2006-08-29
GB0218252D0 (en) 2002-09-11
DE60235603D1 (de) 2010-04-22
JP2003169671A (ja) 2003-06-17
MXPA02008131A (es) 2004-12-13
BRPI0203394B1 (pt) 2015-12-01
BR0203394A (pt) 2004-05-11
RU2002123438A (ru) 2004-03-27
WO2003046013A1 (en) 2003-06-05
US20030124115A1 (en) 2003-07-03
GB2382580B (en) 2003-10-08
RU2225220C1 (ru) 2004-03-10
ES2339426T3 (es) 2010-05-20
ITMI20021803A1 (it) 2003-05-30
JP3860097B2 (ja) 2006-12-20
TWI237056B (en) 2005-08-01
FR2832716A1 (fr) 2003-05-30
GB2382580A (en) 2003-06-04
EP1319712B1 (en) 2010-03-10
EP1319712A3 (en) 2003-11-12
KR100467750B1 (ko) 2005-01-24

Similar Documents

Publication Publication Date Title
AR036384A1 (es) Una proteina de fusion que tiene actividad de eritropoyetina in vivo aumentada
ECSP064643A (es) Proteinas de fusion de glp-1
ATE473011T1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy- terminalen domänen
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
ES2059547T3 (es) Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.
DE60033431D1 (de) Chimärische natriuretische peptide
ATE320449T1 (de) Fusionsprotein mit verbesserter in vivo erythropoietinwirkung
HRP20050354B1 (es)
CR7584A (es) Nuevas proteinas de fusion con trombomodulina dirigidas contra factores tisulares como anticoagulantes
DK1427750T3 (da) Modificerede transferrin-fusionsproteiner
EA200100216A1 (ru) Композиции на основе слитого белка ов и способы их применения
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
ATE433491T1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ATE317441T1 (de) Cathepsin-02-protease
EE03693B1 (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
ATE522563T1 (de) Verzweigte polyalkylenglykole
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
DK1364029T3 (da) Fusionsprotein, der omfatter hirudin og proinsulin eller insulin
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
DE60236796D1 (de) Verzweigte polyalkylenglykole
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
AR025660A1 (es) PRECURSOR DE HIRUDINA, PROCEDIMIENTO PAA LA PREPARACIoN DE LEU-HIRUDINA Y SU EMPLEO PARA LA PREPARACIoN DE LEU-HIRUDINA.
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
ES2310055T3 (es) Quinasa humana dependiente de ciclina (hpnqalre).
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee